One of the world’s leading market research and advisory firms for pharmaceutical and healthcare issues, Decision Resources, finds that the prostate cancer drug market will experience robust 10% annual growth through 2022. The growth is expected the world’s major pharmaceutical markets, including United States, France, Germany, Italy, Spain, the United Kingdom and Japan, and will total $8.6 billion in 2022.

Hormonal therapies ? including abiraterone acetate (Zytiga?; Johnson & Johnson/Janssen Biotech/Janssen Cilag) and enzalutamide (Xtandi?; Medivation/Astellas Pharma) – are expected to continue to dominate the prostate cancer market in patient shares and sales, and will claim more than 80% of the market in 2022.

There will be more therapies positioned for the mCRPC population, making this setting an increasingly crowded and competitive space…

Fueling growth
Pharmaceutical business consultants finds that growth will be fueled by continuing market penetration of abiraterone acetate and enzalutamide and the launch of four additional high-priced therapies, including the 2013 launch of radium Ra 223 dichloride (Xofigo?; Algeta/Bayer HealthCare). The uptake of enzalutamide and its expected label extensions for first-line, chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) and nonmetastatic CRPC (nmCRPC) will drive its overall sales over the second half of the forecast. Business consultants expect that enzalutamide will emerge as the top-selling agent in the prostate cancer market, garnering more than $3 billion in 2022.


“Enzalutamide will benefit greatly from its expected entry into the underserved and untapped nmCRPC setting,” said Decision Resources Senior Business Insights Analyst Khurram Nawaz, M.Sc. “Although enzalutamide will realize more than half of its sales in the commercially lucrative first-line mCRPC setting, we anticipate that sales in nmCRPC will represent nearly 30% of its overall sales in prostate cancer in 2022.”

Advertisement #3

The findings also reveal that emerging therapies forecast to launch through 2022 (including radium Ra 223 dichloride) will capture nearly $2 billion across the seven major markets under study. Three of these therapies will be positioned for the mCRPC population, making this setting an increasingly crowded and competitive space.

Prostate cancer in China
Business consultants at Decision Resources also forecasts a 12% annual growth in sales for prostate cancer therapies in urban China over the next five years, driven mainly by a 50% increase in drug-treated cases. According to the Emerging Markets report entitled Prostate Cancer in China, growth will also be attributed to the launch of four novel therapies in China, including abiraterone acetate, radium Ra 223 dichloride, degarelix (Firmagon?; Ferring Pharmaceutical), cabazitaxel (Jevtana?; Sanofi). While the drug-treated patient population will be small compared to that in the major markets, the combined sales will contribute 15% to the total urban market in 2017.

Photo: Radium Ra 223 dichloride (Xofigo?) discovered by Algeta ASA, a Norwegian biotech, and in-licensed by Bayer. Photo courtesy: Algeta ASA/Bayer.

Copyright ? 2013 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.


Advertisement #5